Compare ISPO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISPO | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 49.3M |
| IPO Year | N/A | 2022 |
| Metric | ISPO | MAIA |
|---|---|---|
| Price | $4.25 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 170.4K | ★ 622.1K |
| Earning Date | 02-23-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,652,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $156.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.87 |
| 52 Week High | $7.17 | $2.74 |
| Indicator | ISPO | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 85.02 | 63.20 |
| Support Level | $4.18 | $1.49 |
| Resistance Level | $4.20 | $1.71 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 100.00 | 76.79 |
Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.